Clinical trial
Study Comparing Simulect Plus Standard Immunosuppression to Standard…
NCT00188825 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00188825 |
|---|---|
| Title | Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant |
| Official title | A Randomized, Double Blind, Placebo Controlled Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans Syndrome in Bilateral Lung and Single Lung Transplant Patients |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | COPD, Emphysema, Alpha-1 Antitrypsan Deficiency |
| Intervention type | Drug, Other |
| Interventions | placebo, basiliximab |
| Enrollment | 22 |
| Start date | May 1, 2004 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Sep 16, 2005 |
| Last update posted | May 4, 2017 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: